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Abstract This multicenter, randomized, open-label phase
III trial (planned enrollment: 700 patients) was conducted to
test the hypothesis that single-agent sunitinib improves
progression-freesurvival(PFS)comparedwith capecitabine
astreatmentforadvancedbreastcancer(ABC).Patientswith
HER2-negative ABC that recurred after anthracycline and
taxane therapy were randomized (1:1) to sunitinib 37.5
mg/day or capecitabine 1,250 mg/m
2 (1,000 mg/m
2 in
patients[65 years) BID on days 1–14 q3w. The indepen-
dent data-monitoring committee (DMC) determined during
the ﬁrst interim analysis (238 patients randomized to
sunitinib, 244 to capecitabine) that the trial be terminated
due to futility in reaching the primary endpoint. No statisti-
cal evidence supported the hypothesis that sunitinib
improved PFS compared with capecitabine (one-sided
P = 0.999). The data indicated that PFS was shorter with
sunitinib than capecitabine (median 2.8 vs. 4.2 months,
respectively; HR, 1.47; 95% CI, 1.16–1.87; two-sided
P = 0.002). Median overall survival (15.3 vs. 24.6 months;
HR, 1.17; two-sided P = 0.350) and objective response
rates (11 vs. 16%; odds ratio, 0.65; P = 0.109) were
numerically inferior with sunitinib versus capecitabine.
While no new or unexpected safety ﬁndings were reported,
sunitinib treatment was associated with higher frequencies
and greater severities of many common adverse events
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DOI 10.1007/s10549-010-0788-0(AEs) compared with capecitabine, resulting in more tem-
porary discontinuations due to AEs with sunitinib (66 vs.
51%). The relative dose intensity was lower with sunitinib
than capecitabine (73 vs. 95%). Based on these efﬁcacy and
safety results, sunitinib should not be used as monotherapy
for patients with ABC.
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Introduction
Advanced breast cancer (ABC) remains an incurable dis-
ease, and new treatment options are urgently needed. For
patients with HER2-positive disease, the introduction of
anti-HER2 therapies has been associated with improved
survival [1, 2]. Progress has been more limited for patients
with HER2-negative disease, however. Currently available
chemotherapeutic agents, while active, yield responses that
are generally short-lived [3]. Capecitabine, an oral ﬂuoro-
pyrimidine carbamate, is an approved standard of care for
ABC. In patients previously treated with anthracyclines/
taxanes, single-agent capecitabine results in an objective
response rate (ORR) of 26%, a median time to tumor
progression (TTP) of 3.4 months, and a median overall
survival (OS) of 8.4 months [4].
Angiogenesis is known to play a key role in tumor
growth and the metastatic spread of breast cancer [5]
consistent with the ﬁnding that expression of vascular
endothelial growth factor (VEGF) and platelet-derived
growth factor receptor beta (PDGFR-b) are associated with
a poorer prognosis [5, 6]. Inhibition of angiogenesis with
the anti-VEGF monoclonal antibody bevacizumab has
been shown to increase progression-free survival (PFS) in a
number of studies when combined with chemotherapy
[7–9], although single-agent bevacizumab is not known to
result in improved outcomes in patients with ABC [10].
In contrast to single-targeted bevacizumab, sunitinib
malate (SUTENT
) is an oral multitargeted tyrosine kinase
inhibitor of VEGFRs and PDGFRs, as well as other
receptor tyrosine kinases [11–13]. Sunitinib is currently
approved multinationally for the treatment of metastatic
renal cell carcinoma (mRCC), and gastrointestinal stromal
tumor (GIST) after disease progression on, or intolerance
to, imatinib treatment [13]. Importantly, single-agent sun-
itinib has demonstrated antitumor activity in heavily pre-
treated patients with metastatic breast cancer (N = 64) in a
phase II trial [14]. Patients received sunitinib 50 mg/day
for 4 weeks followed by 2 weeks off-treatment (Schedule
4/2) in 6-week cycles. The ORR was 11%; stable disease
(SD) for 6 months or more was 5%, leading to a clinical
beneﬁt rate of 16%; and median TTP was 10 weeks. More
recently, continuous daily dosing (CDD) of sunitinib
37.5 mg has been found to provide a feasible and
convenient alternative dosing schedule for patients with
mRCC or GIST [15–17].
In 2006, a multicenter, randomized, open-label phase III
trial (SUN 1107) was initiated to test the hypothesis that
single-agent sunitinib 37.5 mg on the CDD schedule would
be superior to capecitabine in prolonging PFS in patients
with ABC that had recurred after anthracycline and taxane
therapy (or single-agent taxane only if an anthracycline
was not indicated). It was hypothesized that inhibition of
multiple signal transduction pathways in ABC by a multi-
targeted kinase inhibitor would translate into a long-term
efﬁcacy beneﬁt superior to that of a single-agent ﬂuoro-
pyrimidine. However, based on both efﬁcacy and safety
analyses early in the conduct of the study, the trial was
terminated due to futility as determined by the independent
data-monitoring committee (DMC). This article presents
the ﬁnal results of the trial.
Methods
Patients
Eligible patients were female, aged C18 years with mea-
surable, HER2-negative ABC that had recurred after
anthracycline and taxane therapies (or single-agent taxane
treatment if an anthracycline was not indicated) in the
neoadjuvant, adjuvant, and/or advanced disease setting.
Neither more than two chemotherapy regimens in the
advanced setting nor any prior capecitabine treatment
were permitted. Prior hormonal therapy or immunotherapy
in the adjuvant and/or advanced settings was permitted.
An interval of C3 weeks was required between major
surgery or systemic therapy (except hormone therapy) and
initiation of study treatment. Patients were required to
have an Eastern Cooperative Oncology Group perfor-
mance status of 0–2, adequate organ function [including
left ventricular ejection fraction C50% measured by
multigated acquisition (MUGA) scan or echocardiogram
(ECHO)], and resolution of all the acute toxic effects of
prior therapy or surgical procedures to National Cancer
Institute Common Terminology Criteria for Adverse
Events, version 3.0 (NCI CTCAE v3.0) grade B1 (except
alopecia). Brain metastases and cardiovascular disease or
uncontrolled hypertension were also key exclusion
criteria.
The study was conducted in accordance with the Inter-
national Conference on Harmonization Good Clinical
Practice guidelines, the Declaration of Helsinki, and
applicable local regulatory requirements and laws and was
approved by the institutional review board or independent
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123ethics committee of each participating center. All patients
provided written informed consent.
Study design and treatment
This was a multinational, multicenter, randomized, open-
label, phase III clinical trial comparing the efﬁcacy and
safety of single-agent sunitinib versus capecitabine admin-
isteredasﬁrst-,second-orthird-linetherapy insubjectswith
ABC. Patients were randomized 1:1 to treatment with sun-
itinib or capecitabine using an interactive voice random-
ization system. Stratiﬁcation factors of randomization were
visceral disease (yes/no), sensitivity to prior taxane treat-
ment (progression \/C12 months after taxane therapy),
hormone receptor status (positive/negative), and country
(study site location).
Sunitinib was administered orally at 37.5 mg on the
CDD schedule. Patients experiencing severe toxicity were
permitted 1-week periods off treatment as needed; dose
reduction to 25 mg was also permitted. Dose escalation to
50 mg was permitted in patients not experiencing a
response based on Response Evaluation Criteria in Solid
Tumors (RECIST) [18] and experiencing only grade B1
non-hematologic or grade B2 hematologic toxicity attrib-
uted to sunitinib within the ﬁrst 9 weeks of treatment.
Capecitabine was administered orally within 30 min
after the end of a meal at 1,250 mg/m
2 (1,000 mg/m
2 in
patients [65 years) twice daily on days 1–14 every
3 weeks. Dose reduction in response to toxicity was
permitted according to the approved label for capecitabine
[4]. Patients requiring [3 weeks’ dose interruption due
to persistent toxicity attributable to either drug were
considered for discontinuation from the study. Study
treatment was planned to continue until disease progression,
unacceptable toxicity, or consent withdrawal.
Assessments
The primary study endpoint was PFS, deﬁned as the time
from randomization to ﬁrst documentation of objective
tumor progression or death due to any cause, whichever
occurred ﬁrst. Key secondary endpoints were TTP, ORR,
duration of response, OS, and safety. Tumors were imaged
using computed tomography or magnetic resonance imag-
ing at baseline and at 6-week intervals from randomization
until documented disease progression or initiation of a
subsequent anticancer therapy. Additional scans were
performed whenever disease progression was suspected, to
conﬁrm an objective response [partial response (PR) or
complete response (CR)] C4 weeks after initial documen-
tation of response, and at withdrawal from the study
(if [6 weeks since the last assessment). Tumor response
(based on RECIST) was evaluated by the investigators.
Safety was assessed by physical examination and analysis
of adverse events (AEs), hematology, blood chemistry,
vital signs, and cardiac function (using 12-lead electro-
cardiogram and two-dimensional ECHO or MUGA scan-
ning) at regular intervals. Treatment-emergent AEs were
graded using NCI CTCAE v3.0.
Statistical methods
The sample size was determined based on the assumption
that median PFS for patients receiving single-agent
capecitabine was 4.2 months [19]. With no historical data
for sunitinib in this population and assuming that inhibi-
tion of multiple targets in breast cancer would translate
into greater efﬁcacy, it was hypothesized that median PFS
with sunitinib would be 33% higher (5.6 months) and that
PFS of both treatment arms would follow an exponential
distribution. Additional assumptions were that interim
analyses would be performed at 33 and 67% of the total
number of PFS events, with an overall one-sided type I
error of a = 0.025. In order to achieve 90% power to
detect a statistical difference in PFS between the treat-
ment groups and a hazard ratio (HR; sunitinib/capecit-
abine) of 0.75, a minimum of 525 PFS events and target
enrollment of 700 patients were planned. Interim analyses
were planned to allow early stopping of the study for
futility and for efﬁcacy at the time of the second interim
analysis. Jennison and Turnbull’s Rho stopping boundary
(q = 3.0) was used for the futility analysis, and the
O’Brien-Fleming stopping boundary was used for evi-
dence of efﬁcacy [20].
The intent-to-treat (ITT) population comprised all
patients who were randomized. All efﬁcacy analyses,
except for analyses of duration of response (which was
assessed only in responders), were performed on the ITT
population. The as-treated (AT) population included all
patients who received at least one dose of study medication
and was the primary population for evaluating treatment
administration and safety. Descriptive statistics were used
to summarize all baseline characteristics, treatment
administration, compliance, efﬁcacy endpoints, and safety
parameters. Time-to-event endpoints were analyzed by
treatment arm using Kaplan–Meier methods. Between-
treatment comparisons for time-to-event endpoints were
conducted using log-rank tests stratiﬁed by visceral dis-
ease, sensitivity to prior taxane treatment, and hormone
receptor status. HRs and 95% conﬁdence intervals (CIs)
were estimated using Cox proportional hazards models
stratiﬁed by the factors used for the stratiﬁed log-rank tests
and by treatment. Overall relative dose intensities were
determined by averaging the relative dose intensities for
each cycle (cumulative doses for each 21-day cycle divided
by the planned dose for a 21-day cycle).
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Study conduct, patients, and treatment administration
As part of ongoing efﬁcacy and safety review by an
independent DMC, the ﬁrst pre-speciﬁed interim analysis
was planned to be performed after 33% of the planned 525
events had occurred. The Rho stopping boundary for this
futility analysis was a HR C1.04. The analysis took place
in March 2009 when 224 PFS events had occurred; based
on the available PFS data, the HR for PFS was determined
to be 1.49 in favor of capecitabine. With the predeﬁned
stopping boundary having been crossed, the DMC recom-
mended that study enrollment be discontinued.
Between November 2006 and April 2009 when enroll-
ment was stopped, 482 patients had been entered into the
trial at 119 centers worldwide (Europe, 39%; Asia–Paciﬁc,
36%; South America, 15%; North America, 8%; and
Africa, 1%). Data cut-off for the results presented here was
July 10, 2009. The ITT population comprised all 482
patients (sunitinib, 238; capecitabine, 244). Four patients
randomized to the capecitabine arm did not receive treat-
ment. All remaining 478 patients received at least one dose
of study medication and comprised the AT population. The
treatment groups were well balanced for demographic,
disease, and prior treatment characteristics (Table 1). A
total of 36% of patients in the sunitinib arm and 33% in the
capecitabine arm had triple-negative (hormone receptor-
and HER2-negative) disease, and 73 and 72% of sunitinib
and capecitabine patients, respectively, had visceral dis-
ease. Sixty-ﬁve percent of patients in both arms were
considered resistant to prior taxane treatment, and 84% of
patients in both arms had received at least one line of prior
systemic treatment in the advanced setting.
Administration of study treatment is summarized in
Table 2. At the time of data cut-off, patients had received
study drug for a median of 61 days in both treatment arms.
Ninety-seven percent of patients in the sunitinib arm and
80% of patients in the capecitabine arm discontinued the
study, most commonly due to disease progression (63 and
57% of patients in the sunitinib and capecitabine arms;
Fig. 1). Sunitinib dosing was interrupted in 52% of patients
for a median of 10 days, while capecitabine treatment was
interrupted in 46% of patients for a median of 7 days. The
sunitinib dose was reduced in 28% of patients, while
capecitabine was dose-reduced in 35% of patients.
The resulting median overall relative dose intensities
were 73% for sunitinib and 95% for capecitabine.
Efﬁcacy
EfﬁcacyresultsaresummarizedinTable 3.PFS,theprimary
study endpoint, when analyzed using a one-sided log-rank
test, yielded a P value of 0.999 (P = 0.002 when analyzed
using a two-sided test, indicating PFS inferiority for therapy
withsunitinibalone).ThemedianPFSwas2.8 monthsinthe
sunitinib arm and 4.2 months in the capecitabine arm
(Table 3; Fig. 2; HR, 1.47; 95% CI, 1.16–1.87), with 63 and
60% of patients having died or had disease progression at
data cut-off. Median TTP results were nearly identical to the
PFS results (data not shown).
OS was shorter in the sunitinib arm than the capecitabine
arm (15.3 vs. 24.6 months; HR, 1.17; 95% CI, 0.84–1.63;
two-sided log-rank test P = 0.350; Table 3; Fig. 3). At data
cut-off, 33% of sunitinib- and 29% of capecitabine-treated
patients had died.
There were fewer conﬁrmed responses in the sunitinib
arm than in the capecitabine arm (1 CR and 26 PRs vs. 1
CR and 39 PRs, respectively). The corresponding ORRs
were 11 and 16% (Pearson v
2 test P = 0.109; Table 3).
Duration of response was also shorter with sunitinib
(6.9 months; 95% CI, 3.1–8.5) than with capecitabine
(9.3 months; 95% CI, 5.5–9.7). Likewise, with 19 and 26
patients having achieved SD for at least 6 months, the
clinical beneﬁt rate (percent objective responses plus SD
C6 months) was lower with sunitinib (19%) than with
capecitabine (27%; Pearson v
2 test P = 0.045).
Safety
Most patients in the study experienced treatment-related
AEs, and frequencies were similar between the treatment
arms overall (92 and 91% in the sunitinib and capecitabine
arms; Table 4). The ﬁve most commonly reported treat-
ment-related AEs on sunitinib were diarrhea (40%), hand–
foot syndrome (32%), nausea (32%), fatigue (30%), and
vomiting (28%); those on capecitabine were hand–foot
syndrome (61%), diarrhea (34%), nausea (28%), fatigue
(20%), and anorexia (16%). Treatment-related AEs that
were reported at least 10% more frequently on sunitinib
than on capecitabine were vomiting, dysgeusia, hyperten-
sion, thrombocytopenia, hypothyroidism, and decreased
platelet count, while only hand–foot syndrome was repor-
ted at least 10% more frequently on capecitabine.
Treatment-related grade 3/4 AEs were reported more
frequently in the sunitinib arm (53%) than in the capecit-
abine arm (32%). The three most common treatment-related
grade 3/4 AEs were neutropenia (11%), hand–foot syn-
drome (8%), and thrombocytopenia (8%) in the sunitinib
arm and hand–foot syndrome (16%), diarrhea (5%),
and neutropenia (4%) in the capecitabine arm. Likewise,
serious AEs (SAEs) considered related to treatment were
more frequent on sunitinib (16%) than on capecitabine
treatment (5%). In the sunitinib arm, the most frequent
were thrombocytopenia (n = 5) and diarrhea (n = 4); in
the capecitabine arm, diarrhea (n = 6) was most frequent.
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123Seven patients died on study as a result of AEs related to
treatment: ﬁve in the sunitinib arm (one each due to
abnormal hepatic function, cerebral hemorrhage, conges-
tive cardiac failure, hepatic failure, and pulmonary embo-
lism) and two in the capecitabine arm (due to hypotension
and septic shock in one patient and subdural hematoma in
one patient).
Temporary dosing discontinuations/interruptions and
dose reductions due to AEs were required by 66 and 15%
of patients in the sunitinib arm and 51 and 23% of patients
in the capecitabine arm. Hand–foot syndrome led to tem-
porary discontinuations/interruptions or dose reductions in
9% of patients in the sunitinib arm and 31% of patients in
the capecitabine arm. Treatment-related AEs led to
discontinuation from the study in a higher proportion of
patients in the sunitinib arm (12%) than the capecitabine
arm (5%). The most common sunitinib-related AEs leading
to discontinuation were neutropenia and thrombocytopenia
in three patients each, while the most common capecit-
abine-related AE leading to discontinuation was neutro-
penia in four patients.
Discussion
The primary objective of this study was to demonstrate
superior PFS with sunitinib versus capecitabine as mono-
therapy for patients with recurrent, HER2-negative, ABC.
Table 1 Patient, disease, and
prior treatment characteristics at
baseline
ECOG PS: Eastern Cooperative
Oncology Group performance
status; triple-negative: hormone
receptor- and HER2-negative
a Data not reported (n),
sunitinib and capecitabine,
respectively: ECOG PS, 6 and
3; no. involved sites, 2 and 2;
progesterone receptor status, 3
and 2; prior taxane treatment, 0
and 2
b HER2 status not evaluable for
one sunitinib patient and
missing for one capecitabine
patient
Patient characteristics Sunitinib (N = 238) Capecitabine (N = 244)
Age, years
Mean 53 53
Range 25–80 23–80
ECOG PS, n (%)
a
0 142 (60) 126 (52)
1 86 (36) 110 (45)
2 4 (2) 5 (2)
Primary diagnosis, n (%)
Metastatic 228 (96) 233 (95)
Locally recurrent 10 (4) 11 (5)
Histologic classiﬁcation, n (%)
Ductal 202 (85) 218 (89)
Lobular 24 (10) 17 (7)
Other 11 (5) 7 (3)
Location of disease, n (%)
Visceral 173 (73) 175 (72)
Non-visceral 65 (27) 67 (28)
Number of involved sites, n (%)
a
1 52 (22) 64 (26)
C2 184 (77) 178 (73)
Most commonly affected sites, n (%)
Liver 115 (48) 125 (51)
Bone 114 (48) 104 (43)
Lymph node 107 (45) 109 (45)
Lung 101 (42) 91 (37)
Receptor status, n (%)
a
Hormone receptor-positive 148 (62) 160 (66)
Hormone receptor-negative 87 (37) 82 (34)
Triple-negative
b 86 (36) 81 (33)
Prior taxane treatment, n (%)
a
Sensitive 84 (35) 83 (34)
Refractory 154 (65) 159 (65)
Prior lines of systemic therapy for advanced disease, n (%)
0 38 (16) 39 (16)
C1 200 (84) 205 (84)
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123This objective was not met, and the data indicate that PFS
was indeed shorter in the sunitinib arm when compared
with the capecitabine arm (median 2.8 vs. 4.2 months,
respectively; HR, 1.47; 95% CI, 1.16–1.87). The one-sided
log-rank test P value of 0.999 demonstrated that there
was no statistical evidence of sunitinib superiority; the
Table 2 Treatment administration
Sunitinib (N = 238) Capecitabine (N = 240)
Median number of cycles started (range) 4 (1–27) 5 (1–40)
Median number of days on drug (range)
a 61 (1–485) 61 (4–540)
Dosing interruptions,
b n (%) 124 (52) 110 (46)
Median average duration (range), days 10 (3–43) 7 (3–35)
Dosing delays, n (%) NA 109 (45)
Median average duration (range), days NA 7 (3–33)
Dose reductions,
c n (%) 66 (28) 84 (35)
Median relative dose intensity (range), % 73 (5–114) 95 (19–124)
NA: not applicable (only dosing interruptions are possible on a CDD schedule as the study drug is administered every day)
a Total number of dosing days from ﬁrst to last day of treatment
b Deﬁned as C3 consecutive days on which treatment was not given
c Deﬁned as any dose C10% lower than the previous dose
Allocated to sunitinib  (n = 238)
Received sunitinib  (n = 238)
Did not receive sunitinib  (n = 0)
Analyzed for efficacy  (n = 238)
Analyzed for safety  (n = 238)
Discontinued study  (n = 230)
 Disease  progression  (n = 149)
 Adverse  event  (n = 36)
(   r e h t O   n = 14)
  Refused treatment for reason  (n = 9)
  other than adverse event
 Study  termination  (n = 8)
  Health status deterioration  (n = 5)
(   h t a e D   n = 4)
 Protocol  violation  (n = 4)
  Lost to follow-up  ( n = 1)
Allocated to capecitabine  (n = 244)
Received capecitabine  (n = 240)
Did not receive capecitabine  (n = 4)
Randomized (n = 482)
Assessed for eligibility (N = 482)
Analyzed for efficacy  (n = 244)
Analyzed for safety  (n = 240)
Discontinued study  (n = 196)
 Disease  progression  (n = 140)
 Adverse  event  (n = 23)
(   r e h t O   n = 10)
  Refused treatment for reason  (n = 9)
  other than adverse event
 Study  termination  (n = 1)
 Health  status  deterioration  (n = 4)
(   h t a e D   n = 6)
 Protocol  violation  (n = 1)
 Lost  to  follow-up  ( n = 2)
Fig. 1 Patient disposition
(CONSORT ﬂow diagram)
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123two-sided test (P = 0.002) indicated PFS inferiority for
therapy with sunitinib alone.
The differences in OS, a secondary endpoint in the
study, were not statistically signiﬁcant (two-sided log-rank
test P = 0.350), and median OS was numerically shorter in
the sunitinib arm than in the capecitabine arm (15.3 vs.
24.6 months), although the survival curves overlapped
(Fig. 3). The OS results should be interpreted with caution,
since the study was not powered for evaluation of OS and
OS data were not mature [the majority of patients in both
arms were in follow-up at data cut-off, which yielded a
high censoring rate ([65%) in both arms].
Similarly, the ORR obtained in the sunitinib arm
was not statistically different from that obtained in the
capecitabine arm (11 vs. 16%; P = 0.109), and the
duration of response was shorter with sunitinib than
capecitabine (median 6.9 vs. 9.3 months, respectively).
These results again suggest that treatment with sunitinib
was inferior to capecitabine in patients with ABC at the
doses and schedules used in this study.
Sunitinib dosed at 37.5 mg on a CDD schedule in this
population of patients with recurrent ABC yielded a safety
proﬁle consistent with that observed previously with the
approved dosing schedule of 50 mg/day on Schedule 4/2 in
patients with RCC and GIST [13] as well as metastatic
breast cancer [14]. Like previous reports, the most common
AEs observed in this study included constitutional symp-
toms such as diarrhea, nausea, fatigue, and vomiting and
skin toxicities such as hand–foot syndrome. No new or
unexpected safety ﬁndings were reported.
Table 3 Efﬁcacy results
Objective response rate: %
complete responses and partial
responses; NA: not applicable;
clinical beneﬁt rate: % complete
responses, partial responses, and
stable disease C6 months
a One-sided stratiﬁed log-rank
test
b Two-sided stratiﬁed log-rank
test
c Odds ratio
d Pearson v
2 test
Variable Sunitinib
(N = 238)
Capecitabine
(N = 244)
Hazard ratio 95% CI P
Progression-free survival
Events, n (%) 151 (63) 147 (60)
Median, months 2.8 4.2 1.47 1.16–1.87 0.999
a
0.002
b
95% CI 2.4–4.0 3.8–5.5
Overall survival
Events, n (%) 78 (33) 71 (29)
Median, months 15.3 24.6 1.17 0.84–1.63 0.825
a
0.350
b
95% CI 11.4–25.3 12.6–26.0
Objective response rate, % 11 16 0.65
c 0.4–1.1 0.109
d
95% exact CI 8–16 12–22
Duration of response
Events, n (%) 27 (11) 40 (16)
Median, months 6.9 9.3 2.79 1.04–7.46 NA
95% CI 3.1–8.5 5.5–9.7
Clinical beneﬁt rate, % 19 27 0.65
c 0.4–1.0 0.045
d
95% exact CI 15–25 22–33
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123However, sunitinib treatment was associated with higher
frequencies and greater severities of many common AEs
compared with capecitabine. Treatment-related grade 3/4
AEs were reported more frequently with sunitinib than
capecitabine (53 vs. 32%, respectively). Discontinuations
from study due to treatment-related AEs were also more
common with sunitinib than capecitabine (12 vs. 5%).
As previously reported [13, 14], AEs associated with
sunitinib treatment were manageable through dosing
interruption, dose reduction, and/or standard medical
therapies.
The higher frequencies and severities of AEs in the
sunitinib arm led to more temporary discontinuations due
to AEs in the sunitinib arm versus the capecitabine arm
(66 vs. 51%). Median dosing interruptions were longer in
the sunitinib arm (10 vs. 7 days), and the relative dose
intensity of sunitinib treatment was lower than that of
capecitabine treatment (73 vs. 95%).
Based on these results, single-agent sunitinib 37.5 mg
on a CDD schedule is not recommended for treatment of
patients with ABC. There are at least several potential
reasons for the observed outcome of the study: the safety
proﬁle that led to the lower relative dose intensity achieved
with sunitinib; the heavily pretreated, heterogeneous
patient population studied; the lack of sufﬁcient activity of
sunitinib as monotherapy on the CDD schedule; and a lack
of dependency of ABC on pathways inhibited by sunitinib.
It is unknown to what extent each of these factors con-
tributed to the lack of efﬁcacy in the sunitinib arm.
In this study, the comparator was the cytotoxic agent
capecitabine, which exhibits activity and acceptable toler-
ability in this patient population, even when dose reduc-
tions are required. In the face of more frequent and severe
toxicity with sunitinib, less sunitinib was administered.
Population pharmacokinetic analyses in other tumor types,
which have shown that increased sunitinib exposure cor-
relates with improved clinical outcomes, highlight the
importance of maintaining sunitinib dosing [21].
The relatively broad population of patients with ABC
studied across multiple lines of therapy remains a potential
contributing factor. A post-hoc subset analysis failed to
reveal any speciﬁc clinically deﬁned sub-population that
beneﬁted more from sunitinib than from capecitabine
treatment (data not shown). However, the possibility of
speciﬁc biomarker-deﬁned populations that beneﬁted can-
not be excluded. Unfortunately, such biomarkers are still
the subject of preclinical and early-phase clinical research
for antiangiogenic agents.
Table 4 Treatment-related adverse events
a occurring in at least 10% of patients in either treatment group
Adverse event n (%)
Sunitinib (N = 238) Capecitabine (N = 240)
Any grade Grade 3 Grade 4 Any grade Grade 3 Grade 4
Any adverse event 218 (92) 110 (46) 17 (7) 219 (91) 71 (30) 6 (3)
Diarrhea 94 (40) 11 (5) 2 (1) 81 (34) 9 (4) 2 (1)
Hand–foot syndrome 77 (32) 19 (8) 0 146 (61) 38 (16) 0
Nausea 76 (32) 2 (1) 0 68 (28) 1 (\1) 0
Fatigue 71 (30) 13 (6) 2 (1) 49 (20) 3 (1) 0
Vomiting 66 (28) 5 (2) 0 27 (11) 3 (1) 0
Dysgeusia 59 (25) 0 0 11 (5) 0 0
Mucosal inﬂammation 59 (25) 7 (3) 0 36 (15) 2 (1) 1 (\1)
Anorexia 54 (23) 2 (1) 0 38 (16) 1 (\1) 0
Hypertension 46 (19) 8 (3) 1 (\1) 1 (\1) 0 0
Asthenia 41 (17) 14 (6) 1 (\1) 28 (12) 1 (\1) 0
Neutropenia 41 (17) 24 (10) 2 (1) 27 (11) 8 (3) 1 (\1)
Stomatitis 38 (16) 2 (1) 0 20 (8) 0 0
Thrombocytopenia 38 (16) 15 (6) 4 (2) 6 (3) 1 (\1) 2 (1)
Dyspepsia 29 (12) 2 (1) 0 10 (4) 0 0
Hypothyroidism 29 (12) 1 (\1) 0 1 (\1) 0 0
Decreased platelet count 28 (12) 12 (5) 3 (1) 3 (1) 0 0
Headache 27 (11) 2 (1) 0 9 (4) 0 0
Rash 26 (11) 0 0 17 (7) 2 (1) 0
a Maximum CTCAE grade
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in ABC than cytotoxic chemotherapeutic agents such as
capecitabine in this unselected patient population.
Capecitabine exhibited similar antitumor activity com-
pared to historical data: the median PFS of 4.2 months
obtained with capecitabine in this study corresponded
well to the 4.2 months reported in another study of
patients with previously treated metastatic breast cancer
[19]. Similarly, the ORR of 11% in the sunitinib arm of
this study was the same as that observed in a phase II
study of heavily pretreated metastatic breast cancer
patients [14], although the phase II study was per-
formed with the intermittent sunitinib dosing schedule
(50 mg/day, Schedule 4/2).
Lower-than-expected single-agent sunitinib activity in
this patient population is consistent with the results
obtained with other single-agent angiogenesis inhibitors,
such as bevacizumab and sorafenib, in metastatic breast
cancer [10, 22], despite the fact that the spectrum of kinase
inhibition of sunitinib is broader than other commercially
available antiangiogenic agents. Numerous clinical studies
of bevacizumab have been conducted in combination with
chemotherapy, and consequently bevacizumab plus pac-
litaxel or docetaxel are approved for ﬁrst-line use in
patients with HER2-negative metastatic breast cancer
[7–9]. Combination trials of chemotherapy with other
targeted antiangiogenic agents, such as sorafenib, have
demonstrated improved PFS over chemotherapy alone
[23]; however, to date, no targeted agent has demonstrated
robust beneﬁt as a single agent. Therefore, emerging evi-
dence suggests that antiangiogenic agents may be best used
in combination with chemotherapy and/or inhibitors of
other signaling pathways in ABC. Results are pending from
a phase III study comparing sunitinib plus capecitabine
versus capecitabine alone as second-line treatment for
patients with ABC.
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